Arca Biopharma (NASDAQ:ABIO) issued its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($1.86) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.98) by $0.12, Fidelity Earnings reports.
ABIO remained flat at $$15.10 on Thursday. 1,373,640 shares of the company traded hands, compared to its average volume of 505,415. Arca Biopharma has a 52 week low of $4.68 and a 52 week high of $23.04.
Separately, ValuEngine downgraded shares of Arca Biopharma from a “buy” rating to a “hold” rating in a report on Tuesday, January 29th.
Arca Biopharma Company Profile
ARCA biopharma, Inc is a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF).
Receive News & Ratings for Arca Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arca Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.